October 21, 2022 | 2:00 – 3:00 PM Eastern / 11:00 – 12:00 PM Pacific Presenter(s): Drs. Amanda Mixon & Sandra Simmons DOWNLOAD PRESENTATION POWERPOINT (PDF) »
October 11, 2022 | 2:00 – 3:00 PM Eastern / 11:00 – 12:00 PM Pacific Presenter(s): Drs. Amanda Mixon & Sandra Simmons DOWNLOAD PRESENTATION POWERPOINT (PDF) »
October 6, 2022 | 12:00 – 1:00 PM Eastern / 9:00 – 10:00 AM Pacific The session, hosted by the International Society for Pharmacoepidemiology (ISPE), will begin with a brief introduction of the topic and the speakers (moderators, 4-5 min, Drs. Andrew Zullo & Daniela Moga) followed by presentations to address: The existing deprescribing landscape (including existing …
Is there a Role for Pharmacoepidemiology in Deprescribing Research? Read More »
https://youtu.be/6g5nHveow1Y Rigorous evidence to guide deprescribing is limited, and priorities to inform deprescribing research and practice remain unclear. Further, it is not known if there are medication targets or patient groups that are most likely to yield the greatest benefit in improving outcomes to inform allocation of limited healthcare resources. This study, funded as part …
Deprescribing Interventions: Learnings from an Overview of Systematic Reviews Read More »
Elizabeth Bayliss, MD, MSPHSenior Investigator, Institute for Health Research, Kaiser Permanente ColoradoProfessor of Family Medicine, University of Colorado School of MedicineIMPACT Health Care Systems (HCS) CoreUSDeN Data and Resources Core Co-LeaderUSDeN Measures Working Group Leader Cynthia Boyd, MD, MPHDirector, Division of Geriatric Medicine and GerontologyProfessor of Medicine, Epidemiology and Health Policy and ManagementJohns Hopkins University …
Complementary and Integrative Health Interventions to Support Deprescribing of Benzodiazepine Receptor Agonists in Older Adults The US Deprescribing Research Network (USDeN) will soon be seeking applications for large pilot studies that test complementary and integrative health approaches to support deprescribing of benzodiazepine receptor agonists in older adults. The goal of this program is to support …
USDeN Call for Pilot Studies Preparatory to Large Clinical Trials Read More »
Thompson W, Jarbøl D, Nielsen JB, Haastrup P, Pedersen LB. GP preferences for discussing statin deprescribing: a discrete choice experiment. Fam Pract. 2022;39(1):26-31. doi:10.1093/fampra/cmab075 Although there is ample evidence on the benefits of deprescribing for older patients, providers’ deprescribing-related communication preferences are less understood. Given that clinicians often have the greatest influence on patients’ deprescribing …
We are thrilled to announce our 2022-2023 cohort of Junior Investigator Intensive Awardees. The Junior Investigator Intensive program provides dedicated supports and research learning opportunities to help fellows, post-docs, and early-stage faculty succeed with their deprescribing-related research and advance their research careers. This years cohort awardees include 13 outstanding physician, pharmacist, and PhD investigators from …
Presenter: Dr. Daniela Moga is an Associate Professor and Larry H. Spears Endowed Chair in Pharmacogenetics in the College of Pharmacy at University of Kentucky. April 12, 2022 | 2PM ET / 11AM PT The course of Alzheimer’s disease (AD) includes a 10–20-year preclinical period with progressive accumulation of amyloid β plaques and neurofibrillary tangles …
